roflumilast 0.5 MG Oral Tablet [Daliresp]
roflumilast
RxCUI: 1091843
What the CMS Formulary Data Shows for roflumilast 0.5 MG Oral Tablet [Daliresp]
Per the CMS 2026 Part D formulary file, roflumilast 0.5 MG Oral Tablet [Daliresp] (RxNorm concept RXCUI 1091843, generic name roflumilast) appears on 2 distinct formulary files spanning 6 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.5.
Real-world access to roflumilast 0.5 MG Oral Tablet [Daliresp] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 59,491 Part D beneficiaries filled roflumilast 0.5 MG Oral Tablet [Daliresp] in 2023, with total plan-and-beneficiary spending of $60,127,502 and an average per-beneficiary annual cost of $1,010.70. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry roflumilast 0.5 MG Oral Tablet [Daliresp] today.
Coverage Details
- Formularies covering
- 2
- Plans covering
- 6
- Coverage rate
- 0.1%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 59,491
- Total spending
- $60,127,502
- Avg per beneficiary
- $1,010.70
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering roflumilast 0.5 MG Oral Tablet [Daliresp]
6 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | Yes | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | Yes | $34.50 | NY |
| Health New England Medicare Compass (PPO) | HEALTH NEW ENGLAND, INC. | T4 | Yes | $0 | MA |
| Health New England Medicare Value (HMO) | HEALTH NEW ENGLAND, INC. | T4 | Yes | $0 | MA |
| Health New England Medicare Premium (HMO) | HEALTH NEW ENGLAND, INC. | T4 | Yes | $15.80 | MA |
| Health New England Medicare Plus (HMO) | HEALTH NEW ENGLAND, INC. | T4 | Yes | $58.40 | MA |
Frequently Asked Questions
Is roflumilast 0.5 MG Oral Tablet [Daliresp] covered by Medicare Part D?
Yes, roflumilast 0.5 MG Oral Tablet [Daliresp] is covered by 6 Medicare Part D plans (0.1% of all Part D formularies).
What tier is roflumilast 0.5 MG Oral Tablet [Daliresp] on Medicare Part D plans?
roflumilast 0.5 MG Oral Tablet [Daliresp] averages Tier 2.5 across Part D plans, ranging from Tier 1 to Tier 4.
Does roflumilast 0.5 MG Oral Tablet [Daliresp] require prior authorization?
100% of Part D formularies require prior authorization for roflumilast 0.5 MG Oral Tablet [Daliresp]. Step therapy: 0%. Quantity limits: 100%.
How much does Medicare spend on roflumilast 0.5 MG Oral Tablet [Daliresp]?
In 2023, total Medicare Part D spending on roflumilast 0.5 MG Oral Tablet [Daliresp] was $60,127,502, covering 59,491 beneficiaries. The average spend per beneficiary was $1,010.70.
Read our methodology - how this data is sourced, computed, and verified.